Currently, our lead investigational drug, ELX-02, is a eukaryotic ribosomal selective glycoside (ERSG) designed to restore production of functional proteins, suppress nonsense mutations, and overcome nonsense-mediated decay without the limiting toxicities of aminoglycosides. ELX-02 is in Phase 2 clinical trials in cystic fibrosis patients with diagnosed nonsense mutations on one or both alleles.
There is a high-unmet medical need among these patients, as they have a high burden of disease, and few, if any, treatment options available. Our library of novel small molecule eukaryotic ribosomal selective glycoside (ERSG) compounds has been designed to treat rare and ultra-rare premature stop codon diseases.
There is a high-unmet medical need among these patients, as they have a high burden of disease, and few, if any, treatment options available. Our library of novel small molecule eukaryotic ribosomal selective glycoside (ERSG) compounds has been designed to treat rare and ultra-rare premature stop codon diseases.
Services
We're looking for individuals with experience in rare diseases, who share our passion for improving the lives of patients and who are committed to meeting the demands of delivering promising treatments.
If you have a passion for improving the lives of patients with rare diseases and would like to be part of a rapidly growing entrepreneurial culture that promotes diversity, operates through strong teamwork and collaboration, rewards accountability and you like to have fun along the way, we'd love for you to come join us at Eloxx!
If you have a passion for improving the lives of patients with rare diseases and would like to be part of a rapidly growing entrepreneurial culture that promotes diversity, operates through strong teamwork and collaboration, rewards accountability and you like to have fun along the way, we'd love for you to come join us at Eloxx!
We intend to be the global leader in the application of the science of translational read-through and the associated pathway of nonsense mediated decay (NMD). We believe that expanding our expertise across these basic science areas of mRNA regulation, ribosomal function, and protein translation forms a solid foundation to support our discovery and development activities.
Reviews
Be the first to review Eloxx Pharmaceuticals.
Write a Review
